AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31714986 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 779
Study 28274812 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia (33°C)
Number of subjects: 66
Study 28274812 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic normothermia (36.8°C)
Number of subjects: 66
Study 28274812 — intervention group
Group type: EXPERIMENTAL
Intervention: Drowning etiology
Number of subjects: 66
Study 28274812 — intervention group
Group type: COMPARATOR
Intervention: Other respiratory etiologies
Number of subjects: 66
Study 28274812 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 66
Study 25906818 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic (spironolactone 100 mg plus furosemide 20 mg daily)
Number of subjects: 54
Study 25906818 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium-restricted diet (maximum intake of 3 g of sodium per day)
Number of subjects: 54
Study 25906818 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo pill, maintain eating habits)
Number of subjects: 54
Study 25906818 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic (spironolactone plus furosemide)
Number of subjects: 54
Study 25906818 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium-restricted diet
Number of subjects: 54
Study 25906818 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 54
Study 22803688 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2190915 (50-1000 mg single doses; 10-450 mg multiple doses; 10-200 mg in crossover design)
Number of subjects: 0
Study 22803688 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2190915 (≥50 mg)
Number of subjects: 0
Study 22803688 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2190915 (≥150 mg)
Number of subjects: 0
Study 22803688 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21457576 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-energy distal radius fractures (patients)
Number of subjects: 44
Study 21457576 — intervention group
Group type: COMPARATOR
Intervention: Controls (age-matched men without fractures)
Number of subjects: 44
Study 18289576 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 to 120 mg intravesical bacillus Calmette‐Guerin plus 100 mg para‐aminomethylbenzoic acid
Number of subjects: 257
Study 18289576 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 to 60 mg bacillus Calmette‐Guerin plus 100 mg para‐aminomethylbenzoic acid
Number of subjects: 257
Study 18289576 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 to 120 mg bacillus Calmette‐Guerin plus 2.0 gm epsilon aminocaproic acid
Number of subjects: 257
Study 18289576 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 to 60 mg bacillus Calmette‐Guerin plus 2.0 gm epsilon aminocaproic acid
Number of subjects: 257
Study 18289576 — intervention group
Group type: COMPARATOR
Intervention: 100 to 120 mg bacillus Calmette‐Guerin alone
Number of subjects: 257
Study 16688994 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-scalp acupuncture (ESA) applied at points MS6, MS4, MS8, MS9, and MS14, with specific application based on unilateral or bilateral lesions, for 6 weeks.
Number of subjects: 10
Study 16688994 — intervention group
Group type: COMPARATOR
Intervention: Medopa orally, 125 mg 3 times/day for mild, 250 mg 3 times/day for moderate, and 250 mg 4 times/day for severe cases, for 6 weeks.
Number of subjects: 10
Study 12955333 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day (RLX60)
Number of subjects: 0
Study 12955333 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 120 mg/day (RLX120)
Number of subjects: 0
Study 12955333 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12955333 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 0
Study 11101199 — intervention group
Group type: EXPERIMENTAL
Intervention: tedisamil 100 mg b.i.d.
Number of subjects: 48
Study 11101199 — intervention group
Group type: COMPARATOR
Intervention: atenolol 50 mg b.i.d.
Number of subjects: 48
Study 8931841 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Deprivation (3 +/- 1.3 hours of sleep)
Number of subjects: 24
Study 8931841 — intervention group
Group type: COMPARATOR
Intervention: Normal Night's Sleep (7.3 +/- 0.8 hours of sleep)
Number of subjects: 24
Study 1382915 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysine infusion (3-6 g of lysine intravenously followed by 0.3-1.9 g of lysine/kg over 1 hour)
Number of subjects: 15
Study 31780006 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical sesame oil
Number of subjects: 104
Study 31780006 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac gel
Number of subjects: 104
Study 29031894 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Number of subjects: 0
Study 29031894 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacral neuromodulation
Number of subjects: 0
Study 25256135 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief parent-focused behavioral management program
Number of subjects: 100
Study 25256135 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief youth-focused strengths-building program
Number of subjects: 100
Study 25256135 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended parent-focused second-stage programming
Number of subjects: 100
Study 25256135 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended youth-focused second-stage programming
Number of subjects: 100
Study 25256135 — intervention group
Group type: EXPERIMENTAL
Intervention: SMART design
Number of subjects: 100
Study 24745666 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled loxapine (10mg)
Number of subjects: 105
Study 24745666 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 22192151 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary injection of mononuclear bone marrow cells (mBMC)
Number of subjects: 100
Study 22192151 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 20211293 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban, 20 mg once daily
Number of subjects: 14000
Study 20211293 — intervention group
Group type: COMPARATOR
Intervention: Warfarin, dose-adjusted to a target INR of 2.5 (range 2.0-3.0)
Number of subjects: 14000
Study 18035202 — intervention group
Group type: EXPERIMENTAL
Intervention: SC IFN‐beta1a 44 microg TIW (high-dose)
Number of subjects: 677
Study 18035202 — intervention group
Group type: COMPARATOR
Intervention: IM IFN‐betala 30 microg QW (low-dose)
Number of subjects: 677
Study 16253344 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (5-20 mg/day)
Number of subjects: 251
Study 16253344 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex sodium (500-2500 mg/day)
Number of subjects: 251
Study 11897605 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral artesunate
Number of subjects: 18
Study 11897605 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin (DHA)
Number of subjects: 18
Study 10078713 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptastigmine 20 mg three times daily
Number of subjects: 491
Study 10078713 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptastigmine 15 mg three times daily
Number of subjects: 491
Study 10078713 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 491
Study 8545144 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (3 x 400 mg)
Number of subjects: 24
Study 8545144 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (3 x 800 mg)
Number of subjects: 24
Study 8545144 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen (3 x 400 mg and 3 x 800 mg)
Number of subjects: 24
Study 1974509 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (25 mg once daily)
Number of subjects: 61
Study 1974509 — intervention group
Group type: COMPARATOR
Intervention: Labetalol (200 mg twice daily)
Number of subjects: 61
Study 6112925 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 1 g cephaloridine injected intravenously at the start of operations
Number of subjects: 405
Study 6112925 — intervention group
Group type: COMPARATOR
Intervention: Single dose of 1 g cephaloridine instilled into the incision at the end of operations
Number of subjects: 405
Study 6112925 — intervention group
Group type: EXPERIMENTAL
Intervention: Classification of abdominal operations by contamination
Number of subjects: 405
Study 31655161 — intervention group
Group type: EXPERIMENTAL
Intervention: tACS at 40 Hz
Number of subjects: 60
Study 31655161 — intervention group
Group type: COMPARATOR
Intervention: tACS at 5 Hz
Number of subjects: 60
Study 31655161 — intervention group
Group type: COMPARATOR
Intervention: tACS at sensory-motor cortex
Number of subjects: 60
Study 29070709 — intervention group
Group type: EXPERIMENTAL
Intervention: HP-BEEF diet (124 g protein/d; 60% from beef, 40% from plant sources)
Number of subjects: 17
Study 29070709 — intervention group
Group type: COMPARATOR
Intervention: NP-BEEF diet (48 g protein/d)
Number of subjects: 17
Study 29070709 — intervention group
Group type: COMPARATOR
Intervention: NP-PLANT diet (100% from plant-based sources)
Number of subjects: 17
Study 26332304 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive family history (FH)
Number of subjects: 4932
Study 26332304 — intervention group
Group type: COMPARATOR
Intervention: Negative family history (FH)
Number of subjects: 4932
Study 26332304 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall prostate cancer incidence predictors
Number of subjects: 4932
Study 26332304 — intervention group
Group type: EXPERIMENTAL
Intervention: Gleason score ≥7 prostate cancer on biopsy
Number of subjects: 4932
Study 26332304 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval prostate cancer diagnosis
Number of subjects: 4932
Study 25168659 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose glimepiride (0.5 mg/day) with sitagliptin
Number of subjects: 76
Study 25168659 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose glimepiride (1 mg/day) with sitagliptin
Number of subjects: 76
Study 25168659 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose glimepiride (2 mg/day) with sitagliptin
Number of subjects: 76
Study 25168659 — intervention group
Group type: COMPARATOR
Intervention: Control group (high-dose glimepiride)
Number of subjects: 76
Study 22030323 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 200
Study 22030323 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stent (BMS)
Number of subjects: 200
Study 19926054 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) plus intravenous sodium bicarbonate (NaHCO3)
Number of subjects: 10
Study 17143601 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg AZD5438
Number of subjects: 12
Study 17143601 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg AZD5438
Number of subjects: 12
Study 17143601 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg AZD5438
Number of subjects: 12
Study 17143601 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 14712468 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% racemic bupivacaine alone (group A)
Number of subjects: 23
Study 14712468 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% racemic bupivacaine with epinephrine (group B)
Number of subjects: 23
Study 14712468 — intervention group
Group type: COMPARATOR
Intervention: 0.5% racemic bupivacaine without epinephrine (group A)
Number of subjects: 23
Study 11335696 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient with left neglect
Number of subjects: 1
Study 11335696 — intervention group
Group type: COMPARATOR
Intervention: Healthy age-matched control subjects
Number of subjects: 1
Study 9744131 — intervention group
Group type: EXPERIMENTAL
Intervention: Buddy condition (mutual support between clinic sessions)
Number of subjects: 172
Study 9744131 — intervention group
Group type: COMPARATOR
Intervention: Solo condition (no mutual support)
Number of subjects: 172
Study 8058981 — intervention group
Group type: EXPERIMENTAL
Intervention: IS-5-MN (100 mg)
Number of subjects: 50
Study 8058981 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 3197367 — intervention group
Group type: EXPERIMENTAL
Intervention: triazolam, 1.0 mg
Number of subjects: 62
Study 3197367 — intervention group
Group type: EXPERIMENTAL
Intervention: triazolam, 1.5 mg
Number of subjects: 62
Study 3197367 — intervention group
Group type: EXPERIMENTAL
Intervention: morphine, 0.15 mg/kg
Number of subjects: 62
Study 3197367 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 62
Study 31815645 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 60
Study 31815645 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 60
Study 28598510 — intervention group
Group type: EXPERIMENTAL
Intervention: ticagrelor
Number of subjects: 6792
Study 28598510 — intervention group
Group type: COMPARATOR
Intervention: clopidogrel
Number of subjects: 6792
Study 26518433 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric Lavage (GL)
Number of subjects: 500
Study 26518433 — intervention group
Group type: COMPARATOR
Intervention: No Lavage
Number of subjects: 500
Study 24417069 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascoril expectorant (Glenmark) at a standard dose
Number of subjects: 16312
Study 21482606 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsurgical periodontitis treatment before 21 weeks' gestation
Number of subjects: 411
Study 21482606 — intervention group
Group type: COMPARATOR
Intervention: Control group (treated after delivery)
Number of subjects: 411
Study 21482606 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvement in maternal periodontal health
Number of subjects: 411
Study 19558681 — intervention group
Group type: COMPARATOR
Intervention: Azoles
Number of subjects: 965
Study 19558681 — intervention group
Group type: COMPARATOR
Intervention: Echinocandins
Number of subjects: 965
Study 19558681 — intervention group
Group type: COMPARATOR
Intervention: Anidulafungin
Number of subjects: 965
Study 17676450 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic endonasal trans‐sphenoidal approach (EETSS)
Number of subjects: 20
Study 17676450 — intervention group
Group type: COMPARATOR
Intervention: Microsurgical endonasal trans‐sphenoidal approach (SMETSS)
Number of subjects: 20
Study 16280028 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg melatonin
Number of subjects: 14
Study 16280028 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 11987005 — intervention group
Group type: EXPERIMENTAL
Intervention: Active spinal cord injured (SCI) males
Number of subjects: 17
Study 11987005 — intervention group
Group type: COMPARATOR
Intervention: Able-bodied male controls
Number of subjects: 17
Study 9568411 — intervention group
Group type: EXPERIMENTAL
Intervention: Laceran 10% urea lotion
Number of subjects: 60
Study 9568411 — intervention group
Group type: COMPARATOR
Intervention: Urea-free Laceran lotion base
Number of subjects: 60
Study 7713825 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased muscle glycogen from 90.3 +/- 6.0 to 124.7 +/- 10.8 mmol/kg wet wt
Number of subjects: 12
Study 7713825 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced muscle glycogen from 96.2 +/- 6.6 to 53.7 +/- 6.0 mmol/kg
Number of subjects: 12
Study 2468300 — intervention group
Group type: EXPERIMENTAL
Intervention: Isovolemic hemodilution with 500 mL of 10% hydroxyethyl starch 200
Number of subjects: 24
Study 2468300 — intervention group
Group type: COMPARATOR
Intervention: Sham dilutions (placebo)
Number of subjects: 24
Study 193642 — intervention group
Group type: EXPERIMENTAL
Intervention: POCC (procarbazine, 100 mg/m2/day orally, Days 1‐14; vincristine, 2 mg iv, Days 1 and 8; cyclophosphamide, 600 mg/m2 iv, Days 1 and 8; and CCNU, 60 mg/m2 orally, Day 1)
Number of subjects: 23
Study 193642 — intervention group
Group type: COMPARATOR
Intervention: COM (cyclophosphamide, 2000 mg/m2 iv, Day 1; vincristine, 2 mg iv, Day 1; and methotrexate, 30 mg/m2 iv, Day 15)
Number of subjects: 23
Study 193642 — intervention group
Group type: EXPERIMENTAL
Intervention: Both chemotherapy programs
Number of subjects: 23
Study 193642 — intervention group
Group type: EXPERIMENTAL
Intervention: POCC
Number of subjects: 23
Study 31915152 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher triglyceride levels
Number of subjects: 494451
Study 31915152 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher LDL-cholesterol levels
Number of subjects: 494451
Study 31915152 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher body fat and visceral body fat distribution
Number of subjects: 494451
Study 31915152 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolically 'favourable adiposity' phenotype
Number of subjects: 494451
Study 31286632 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive education and pedometer walking exercise training (PEPWET)
Number of subjects: 150
Study 31286632 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer walking exercise training (PWET)
Number of subjects: 150
Study 31286632 — intervention group
Group type: COMPARATOR
Intervention: Pedometer walking exercise (PWE)
Number of subjects: 150
Study 27422483 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelium-in (endo-in)
Number of subjects: 18
Study 27422483 — intervention group
Group type: COMPARATOR
Intervention: Endothelium-out (endo-out)
Number of subjects: 18
Study 25100406 — intervention group
Group type: EXPERIMENTAL
Intervention: Repair (n = 19)
Number of subjects: 20
Study 25100406 — intervention group
Group type: COMPARATOR
Intervention: Replacement (n = 21)
Number of subjects: 20
Study 23714798 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosthetically guided maxillofacial surgery
Number of subjects: 7
Study 23714798 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard preplating technique)
Number of subjects: 7
Study 21976398 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated mycophenolate sodium (EC-MPS) with standard-dose glucocorticoids
Number of subjects: 81
Study 19736028 — intervention group
Group type: EXPERIMENTAL
Intervention: 12% sucrose solution (1cc)
Number of subjects: 111
Study 19736028 — intervention group
Group type: COMPARATOR
Intervention: Distilled water (control group)
Number of subjects: 111
Study 17032876 — intervention group
Group type: EXPERIMENTAL
Intervention: Periventricular WMH (PVWMH)
Number of subjects: 56
Study 17032876 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep WMH (DWMH)
Number of subjects: 56
Study 17032876 — intervention group
Group type: EXPERIMENTAL
Intervention: Frontal PVWMH
Number of subjects: 56
Study 17032876 — intervention group
Group type: EXPERIMENTAL
Intervention: Smooth PVWMH
Number of subjects: 56
Study 17032876 — intervention group
Group type: COMPARATOR
Intervention: Control group (19 subjects with no or limited WMH)
Number of subjects: 56
Study 15648991 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive pressure ventilation with PEEP set at 0, 5 and 10 cmH2O
Number of subjects: 42
Study 15648991 — intervention group
Group type: COMPARATOR
Intervention: Pressure support ventilation with PEEP set at 0, 5 and 10 cmH2O
Number of subjects: 42
Study 11798687 — intervention group
Group type: EXPERIMENTAL
Intervention: Xuezhikang 1.2 g/d Bid, p.o
Number of subjects: 91
Study 11798687 — intervention group
Group type: COMPARATOR
Intervention: gemfibrozil 1.2 g/d Bid, p.o
Number of subjects: 91
Study 7781417 — intervention group
Group type: EXPERIMENTAL
Intervention: ECCE (extracapsular cataract extraction)
Number of subjects: 140
Study 7781417 — intervention group
Group type: EXPERIMENTAL
Intervention: ECCE + IOL (ECCE and intraocular lens implantation)
Number of subjects: 140
Study 7781417 — intervention group
Group type: EXPERIMENTAL
Intervention: Lensectomy
Number of subjects: 140
Study 2086165 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (10 mg once a day for 7 days)
Number of subjects: 8
Study 2086165 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 86051 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.7 units/kg of intermediate factor-VIII concentrate
Number of subjects: 6
Study 86051 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.0 units/kg of intermediate factor-VIII concentrate
Number of subjects: 6
Study 30735680 — intervention group
Group type: EXPERIMENTAL
Intervention: Active ECAT (eye-gaze contingent attention training)
Number of subjects: 66
Study 30735680 — intervention group
Group type: COMPARATOR
Intervention: Control condition (free interpretation without gaze-contingent feedback)
Number of subjects: 66
Study 28251618 — intervention group
Group type: EXPERIMENTAL
Intervention: Powered Respiratory Protective Suit (PRPS ensemble)
Number of subjects: 30
Study 28251618 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyprotect 12 ensemble
Number of subjects: 30
Study 28251618 — intervention group
Group type: COMPARATOR
Intervention: Unprotected (control)
Number of subjects: 30
Study 24119034 — intervention group
Group type: EXPERIMENTAL
Intervention: Clear corneal vitrectomy
Number of subjects: 20
Study 24119034 — intervention group
Group type: COMPARATOR
Intervention: Standard 25-gauge pars plana vitrectomy with corneal incision cataract surgery
Number of subjects: 20
Study 22373942 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (1200 mg/day)
Number of subjects: 50
Study 22373942 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 19304472 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual endothelin receptor antagonists (ERAs)
Number of subjects: 0
Study 19304472 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective endothelin receptor antagonists (ERAs)
Number of subjects: 0
Study 19304472 — intervention group
Group type: COMPARATOR
Intervention: Various endothelin receptor antagonists (ERAs)
Number of subjects: 0
Study 17460732 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention consisting of an educational curriculum at school, conducted by trained teachers, including a short video and distribution of booklets to children and parents.
Number of subjects: 11230
Study 17460732 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 11230
Study 16246657 — intervention group
Group type: EXPERIMENTAL
Intervention: Quick Start with contraceptive patch (Group 1, n=30)
Number of subjects: 60
Study 16246657 — intervention group
Group type: COMPARATOR
Intervention: Traditional initiation (first day of next menses) (Group 2, n=30)
Number of subjects: 60
Study 11967245 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 43